Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Clinical trial NCT06458595 · RECRUITING
Trial details
- NCT number
- NCT06458595
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-28
- Primary completion
- 2026-03-31
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.